Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Brain and Central Nervous System Tumors
Interventions: Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 5 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2029
U.S. locations: 5
States / cities: Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more

Conditions: Colon Polyps
Interventions: Polp removal and identification, colon polyp removal, ETMI colonoscope (ETMI scope is a FDA approved device); Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Adenocarcinoma of the Prostate
Interventions: Stereotactic Radiosurgical Boost, Casodex, Leuprolide; Radiation · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Venetoclax, Ibrutinib; Drug
Lead sponsor: Michael Choi; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: First Episode Psychosis (FEP), At Risk Mental State (ARMS)
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 12 Years to 30 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Osteosarcoma
Interventions: Cyclophosphamide and Sirolimus; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Head and Neck Cancer
Interventions: paclitaxel; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 28
States / cities: Palo Alto, California • Stanford, California • Tampa, Florida + 21 more

Conditions: Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
Interventions: Imexon; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Tucson, Arizona • Rochester, New York

Conditions: CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions: SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab; Drug · Radiation
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Interventions: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs); Biological
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: BK Virus Nephropathy, BK Virus Infection
Interventions: Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel); Biological
Lead sponsor: AlloVir; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 33
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 27 more

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: Venetoclax, Azacitidine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 58
States / cities: Fullerton, California • Los Angeles, California • Torrance, California + 50 more

Conditions: High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: Atovaquone, Radiation Therapy; Drug · Radiation
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 25 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Complication of Surgical Procedure
Interventions: Incisional Neg Pressure Wound Therapy (Prevena™), Standard of Care wound therapy; Device · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Barrett Esophagus, Gastroesophageal Reflux
Interventions: NBI-AFI imaging, Standard Endoscopy; Other
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Kansas City, Missouri • Charleston, South Carolina

Conditions: Violence
Interventions: Individual intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: High Grade Glioma
Interventions: LITT, Radiation therapy, Temozolomide; Procedure · Radiation · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions: MDNA11, Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Medicenna Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 7
States / cities: San Diego, California • San Francisco, California • Santa Monica, California + 4 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Intravenous vitamin C; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Brain Tumor, Recurrent
Interventions: Photofrin photodynamic therapy.; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Continuous Positive Airway Pressure, High Altitude Pulmonary Edema
Interventions: CPAP mask system, Nifedipine 30 MG, CPAP mask system without PEEP; Device · Drug
Lead sponsor: CommonSpirit Health; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Breckenridge, Colorado

Conditions: Glioma, Glioblastoma
Interventions: Focused ultrasound (FUS); Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Charlottesville, Virginia + 1 more

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Interventions: Vitamin A Compound, Best Practice; Dietary Supplement · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Detection and Classification of Colon Polyps

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Reducing the Duration of Untreated Psychosis in the United States

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Imexon for Relapsed Follicular and Aggressive Lymphomas

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

Incisional Negative Pressure Dressing on Clean Closed Groin Incisions

Novel Imaging Techniques in Barrett's Esophagus

Effects of Individual Intervention for Men in Focused Deterrence Program

Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas

A Beta-only IL-2 ImmunoTherapY Study

Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

Evaluating the Utility of Continuous Positive Airway Pressure in the Treatment of High Altitude Pulmonary Edema

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant